ÐźÅͨ·ÊÇÓÉ´Óϸ°ûĤ¡¢°û½¬µ½Ï¸°ûºËһϵÁеĵ°°×·Ö×Ó£¬Í¨¹ýµ°°×Á×ËữºÍµ°°×»¥×÷µÈÐÎʽ´®ÁªÆðÀ´µÄµ°°×·Ö×ÓÐźŴ«µ¼ÍøÂç¡£ÔÚ¼²²¡µÄ·¢Éú¡¢·¢Õ¹£¬Ï¸°û±íÐ͵ÈÉúÎïÏÖÏóµÄ±³ºó£¬ÐźÅͨ·µÄµ÷±äÆð×Å·Ö×Ó²ãÃæµÄÖ§³Å×÷Óá£ÐźÅͨ··ÖÎöÊÇÖ×Áöѧ¡¢²¡Àíѧ¡¢ÃâÒßѧ¡¢Ï¸°ûÉúÎïѧ¡¢Éñ¾­ÉúÎïѧ¡¢Ò©ÀíѧµÈһϵÁÐÒÔ»úÀí̽Ë÷ΪÑо¿Ä¿µÄµÄ¿ÆÑй¤×÷µÄ±Ø¾­Ö®Â·¡£

       È»¶ø£¬Ï¸°ûÖдæÔÚ¶àÌõÐźÅͨ·£¬ËüÃDz¢²»¹ÂÁ¢´æÔÚ£¬»á´®Áª½»²æÐγɵĸ´ÔÓÐźÅÍøÂ磨Cross-talk£©¡£¸ÃÐźÅÍøÂçÔÚϸ°ûÊܵ½°ûÍâ´Ì¼¤ºó½«ÐźÅͨ¹ý¼¶Áª·Å´ó¡¢·ÖÉ¢µ÷½ÚµÈ·½Ê½´«Èë°ûÄÚ£¬ÒýÆðһϵÁи´ÔÓµÄÐźŸı䣬½ø¶ø²úÉú×ۺϵÄϸ°ûÓ¦´ð¡£Ãæ¶Ô¸´ÔÓÑо¿ÏÖÏó£¬ÍùÍù»áÓжàÌõͨ·»á·¢Éúµ÷±ä¡£ÈçºÎÑ¡ÔñÖ÷Òªµ÷±äµÄͨ·£¿ÊÇÀ§ÈÅÑо¿ÈËÔ±µÄÖ÷ÒªÄÑÌâÖ®Ò»£¬¶ø´«Í³µÄ¼¼ÊõÈçWesten blotµÈ²»Äܽâ¾ö¡£

        Éý¼¶°æ ÐźÅͨ·¹ãɸ¿¹ÌåоƬ£¨CSP100 Plus£©ÊÇÔÚÔ­Ö×ÁöÐźÅͨ·Á×Ëữ¹ãÆ×ɸѡ¿¹ÌåоƬ£¨CSP100£©µÄ»ù´¡ÉÏÉý¼¶Íê³ÉµÄ¹ãɸоƬ¡£¸ÃоƬ²ÉÓÃÈýά¸ß·Ö×ÓĤרÓü¼Êõ£¬ÔÚƬ»ùÉϹ²¼Û½áºÏ304ÖÖ¸ßÌØÒ쿹Ì壬ÆäÖÐÁ×Ëữ¿¹Ìå157ÖÖ£¬·ÇÁ×Ëữ¿¹Ìå147ÖÖ¡£Ò»ÕÅCSP100 PlusоƬ¿ÉÒÔͬʱ¶Ô16ÌõÐźÅͨ·½øÐÐɸѡºÍ±È½Ï¡£Õâ16ÌõÐźÅͨ·ÊÇÉúÎïҽѧÑо¿Öг£¼ûÒ²ÊÇÖØÒªµÄͨ·£¬ËüÃǹ㷺²ÎÓëµ½Ö×Áö¡¢ÃâÒß¡¢ÐÄѪ¹Ü¡¢Éñ¾­ÏµÍ³¡¢ËðʧÐÞ¸´µÈ¶àÖÖ²¡ÀíÉúÀí¹ý³ÌÖС£Òò´Ë£¬CSP100 PlusоƬ¿ÉÒÔÊÊÓÃÓÚ¶àÖÖ¼²²¡ÓëÒ©ÎïÑо¿Ä£Ð͵ÄÐźÅͨ·ɸѡ¹¤×÷¡£Í¬Ê±£¬¼¹×µ¶¯ÎïµÄÁ×Ëữλµã¾ß±¸±£ÊØÐÔ£¬Ð¾Æ¬ÉϵĿ¹Ì嶼ÊÇÒÔÄ¿±êµ°°×µÄÎïÖÖ±£ÊضàëÄÐòÁÐΪ¿¹Ô­½øÐÐÉèÖã¬ËùÒÔ£¬CSP100 PlusоƬÉϵĿ¹Ìå¾ßÓÐÒ»¶¨µÄÎïÖÖͨÓÃÐÔ¡£

|   ¿¹ÌåоƬÌصã

¡ñ  Ð¾Æ¬¹æ¸ñΪ76 x 25 x 1 mm£»

¡ñ  ÊµÏÖ16ÌõÐźÅͨ·ȫÃæɸÑ¡£»

¡ñ  Ã¿ÖÖ¿¹ÌåÉèÖÃ6´Î¼¼ÊõÖظ´£»

¡ñ  ÊÊÓÃÓÚ×éÖ¯¡¢Ï¸°ûµÈ¶àÀàÐÍÑù±¾£»

¡ñ  5×10⁶ϸ°û¡¢200 µg×ܵ°°×Á¿¼´¿ÉÂú×ãʵÑ飻

¡ñ  ¿ÉͬʱÌṩÁ×ËữºÍµ°°×±í´ïÁ½Ì×Êý¾Ý£»

¡ñ  ¿ÉͨÓÃÓÚÈË¡¢Ð¡Êó¡¢´óÊóµÈ¶àÀàÐÍģʽÉúÎï¼ì²â¡£

|   Ð¾Æ¬¸²¸Çͨ·

 µã»÷ÏÂÔؼì²âÁбí 

|   ¿¹ÌåоƬԭÀí

|   ¿Í»§°¸Àý£ºCSP100оƬЭÖú·¢ÏÖÄÉÃ×Ò©Îï×÷ÓûúÀí

       È±Ê§ºÍÍ»±äÖøÃûµÄÒÖ°©»ùÒòPTEN ÒѾ­Ôںܶ఩֢Öб»·¢ÏÖ£¬ÓÉÓÚPTEN¿ÉÖ±½Ó²ÎÓëµ½¿¹Ö×ÁöµÄÃâÒßµ÷½Ú¡£Òò´Ë£¬Èç¹ûÔÚ°©Ö¢ÖÐÖØпªÆôPTEN»ùÒòµÄ±í´ï£¬Í¨¹ýÔöÇ¿¿¹Ö×ÁöÃâÒߣ¬ÊÇ·ñÄܹ»ÖÎÁÆÖ×ÁöÄØ£¿ÕâÊÇÒ»¸ö·Ç³£Óд´ÒâµÄ¼ÙÉè¡£

       Ñо¿ÈËԱͨ¹ýPTEN mRNA ÄÉÃ׿ÅÁ££¨mPTEN@NP£©ÔØҩϵͳ£¨Í¼1A£©´«µÝmRNAµ½»ùÒòȱʧºÍÍ»±äµÄPTEN-Cap8 ºÍB16F10 ϸ°ûÖУ¬»Ö¸´ÁËPTEN»ùÒòµÄ±í´ï£¬¹ûÈ»´ïµ½ÁËÓÐЧÒÖÖÆÇ°ÁÐÏÙ°©Ï¸°ûÉú³¤£¬´Ù½øÆäµòÍöµÄÁÆЧ£¨Í¼1B£©¡£¶ÔÓÚÄÉÃ×Ò©ÎïÁìÓòµÄ¿Æѧ¼ÒÀ´Ëµ£¬²ÄÁÏ¿ÆѧÊDZ¾ÐУ¬Ñо¿ÖÐÄÉÃ×Ò©ÎïµÄ¸ÄÔìÍùÍù»á»¨·ÑÁË´óÁ¿¾«Á¦¡£¶ø¶ÔÓÚPTENÕâÖÖÃ÷ÐÇ·Ö×ӵĵ÷¿Ø£¬ÓÖÊƱػáÒýÆðһϵÁи´ÔÓÐźÅͨ·µÄ±ä»¯¡£ÈçºÎ¸ßЧµØɸѡÕâЩÐźÅͨ·³ÉΪÐèÒªÃæ¶ÔµÄÐÂÎÊÌ⣿

       Ñо¿ÈËÔ±Óëk8¿­·¢(Öйú)Õ¹¿ª½ôÃܺÏ×÷£¬Í¨¹ýCSP100ÐźÅͨ·Á×Ëữ¹ãɸ¿¹ÌåоƬ¼¼Êõ£¬Í¬Ê±¶ÔmPTEN@NPsºÍPBS¶ÔÕÕ×é·Ö±ð´¦ÀíµÄPTEN-Cap8ϸ°ûÖеÄ16ÌõÐźÅͨ·½øÐÐÁ˹㷺ɸѡ£¨Í¼1C£©¡£Ð¾Æ¬½á¹ûÏÔʾ¶àÌõÐźÅͨ·¾ùΧÈÆPTEN»ùÒòµÄ±í´ï·¢ÉúÁËÏÔÖø±ä»¯£¬ÓÈÆäÊÇ×ÔÊÉͨ·Ïà¹Øµ°°×Á×Ëữµ÷±äÓÈΪÃ÷ÏÔ£¨Í¼1D£©¡£Í¨¹ýWestern blotʵÑ飬Ñо¿ÈËԱ֤ʵÁËmPTEN@NP¿ÉÏÔÖøÔö¼Ó×ÔÊÉÏà¹Øµ°°×µÄ±í´ï¡£²¢Í¨¹ýһϵÁÐ×ÔÊÉÏà¹Ø¹¦ÄÜʵÑ飬Ã÷È·ÁË×ÔÊÉͨ¹ýÓÕµ¼ËðÉËģʽʶ±ð·Ö×Ó (DAMPs)£¬¼Ì¶øÔö¼ÓÃâÒßÔ­ÐÔϸ°ûËÀÍö£¨ICD£©ÊÇmPTEN@NP·¢»Ó¿¹Ö×Áö×÷ÓõĹؼü»úÖÆ¡£

ÏêϸÄÚÈݵã»÷²é¿´£ºhttps://mp.weixin.qq.com/s/dLS0iwFaUETn242avG2_lQ

|   ¿Í»§ÎÄÏ×

[1]. Bing Yao, Sha Zhu, Xiyi Wei, et al. The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression.Mol Cancer. 2022 May 27;21(1):119. £¨ÄÏ·½Ò½¿Æ´óѧµÚÒ»¸½ÊôÒ½Ôº£©IF=27.401

[2]. Chen C, Ma Q, Deng P, et al. 1800 MHz Radiofrequency Electromagnetic Field Impairs Neurite Outgrowth Through Inhibiting EPHA5 Signaling. Front Cell Dev Biol. 2021 Apr 12;9:657623.£¨µÚÈý¾üÒ½´óѧ£©IF=6.684

[3]. Liu L, Wang Y, Geng C, et al. CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways. Front Oncol. 2021 Jun 7;11:655302. £¨É½¶«´óѧÆë³ҽѧԺÆë³ҽԺ£©

[4]. Zhou Y, Fu B, Xu X, et al. PBX1 expression in uterine natural killer cells drives fetal growth. Sci Transl Med. 2020 Apr 1;12(537): eaax1798. £¨ÖпÆÔºÏÈÌìÃâÒßÓëÂýÐÔ²¡ÖصãʵÑéÊÒ£©IF=17.1

[5]. Zhou XX, Wang RL, Xue B, et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. J. Clin. Invest. 2019, 129: 676-693. £¨Ìì½òÒ½¿Æ´óѧ×ÜÒ½Ôº£©IF=14.808

[6]. Gu CM, Liu YJ, Yin Z, et al. Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway. Mol Ther Nucleic Acids. 2019 Jun 7;16:1-14. £¨ôßÄÏ´óѧҽѧԺÖÐÎ÷Ò½½áºÏÑо¿Ëù£©IF=8.8

[7]. Liu D, Zhang XX, Li MC, et al. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018 Apr 30;9(1):1739. £¨Î人ͬ¼ÃÒ½Ôº£©IF=14.919

[8]. Ge XW, Chen JF, Li L, et al. Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphomaby inducing apoptosis. Cell Death Dis. 2018 Dec 18;10(1):8. £¨¸´µ©´óѧÖÐɽҽԺ²¡Àí¿Æ£©IF=8.469

[9]. Wu QY, Zhu YY, Liu Y, et al. CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia. Cell Death Dis. 2018 Jul 10;9(7):774. £¨ÐìÖÝÒ½¿Æ´óѧ¸½ÊôÒ½Ôº£©IF=9.0

[10]. Xu YZ, Dong BJ, Wang JF, et al. Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma. Oncoimmunology. 2018 Sep 25;7(12):e1502130.£¨ÉϺ£½»Í¨´óѧҽѧԺÈʼÃÒ½Ôº£©IF=8.110

[11]. Du F, Sun LN, Chu Y, et al. DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways. Cancer Commun (Lond). 2018 Jul 5;38(1):45. £¨µÚËľüÒ½´óѧÖ×ÁöÉúÎïѧ¹ú¼ÒÖصãʵÑéÊÒ£©IF=10.392

[12]. Ling SB, Xie HY, Yang F, et al. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol. 2017 Feb 28;10(1):59. £¨Õã½­´óѧµÚÒ»¸½ÊôÒ½Ôº£©IF=17.388

[13]. Zhu RR, Wang QX, Zhu YJ, et al. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomater. 2016 Jan;29:320-332. £¨Í¬¼ÃÒ½Ôº£©IF=9.7